[1] Parkinson J. An essay on the shaking palsy:1817[J]. J Neuropsychiatry Clin Neurosci, 2002, 14:223-236. [2] Choi HG, Lim JS, Lee YK, Sim S, Kim M. Mortality and cause of death in South Korean patients with Parkinson's disease:a longitudinal follow-up study using a national sample cohort[J].BMJ Open, 2019, 9:e29776. [3] Hobson P, Meara J. Mortality and quality of death certification in a cohort of patients with Parkinson's disease and matched controls in North Wales, UK at 18 years:a community-based cohort study[J]. BMJ Open, 2018, 8:e18969. [4] Baille G, Chenivesse C, Perez T, Machuron F, Dujardin K, Devos D, Defebvre L, Moreau C. Dyspnea:an underestimated symptom in Parkinson's disease[J]. Parkinsonism Relat Disord, 2019, 60:162-166. [5] Moreau C, Devos D, Baille G, Delval A, Tard C, Perez T, DanelBuhl N, Seguy D, Labreuche J, Duhamel A, Delliaux M, Dujardin K, Defebvre L. Are upper-body axial symptoms a feature of early Parkinson's disease[J]?PLoS One, 2016, 11:e0162904. [6] Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology[J]. Clin Geriatr Med, 2020, 36:1-12. [7] Vijayan S, Singh B, Ghosh S, Stell R, Mastaglia FL. Brainstem ventilatory dysfunction:a plausible mechanism for dyspnea in Parkinson's disease[J]?Mov Disord, 2020, 35:379-388. [8] Liu N, Fu C, Yu H, Wang Y, Shi L, Hao Y, Yuan F, Zhang X, Wang S. Respiratory control by phox2b-expressing neurons in a locus coeruleus-preB?tzinger complex circuit[J]. Neurosci Bull, 2021, 37:31-44. [9] Dickson DW. Neuropathology of Parkinson disease[J].Parkinsonism Relat Disord, 2018, 46 Suppl 1:30-33. [10] Fernandes-Junior SA, Carvalho KS, Moreira TS, Takakura AC.Correlation between neuroanatomical and functional respiratory changes observed in an experimental model of Parkinson's disease[J]. Exp Physiol, 2018, 103:1377-1389. [11] Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension[J]. Mov Disord Clin Pract, 2017, 4:298-308. [12] Gibbons CH, Freeman R. Orthostatic dyspnea:a neglected symptom of orthostatic hypotension[J]. Clin Auton Res, 2005, 15:40-44. [13] Fanciulli A, Leys F, Falup-Pecurariu C, Thijs R, Wenning GK.Management of orthostatic hypotension in Parkinson's disease[J]. J Parkinsons Dis, 2020, 10(s1):S57-64. [14] Oliveira LM, Oliveira MA, Moriya HT, Moreira TS, Takakura AC. Respiratory disturbances in a mouse model of Parkinson's disease[J]. Exp Physiol, 2019, 104:729-739. [15] Evans KC. Cortico-limbic circuitry and the airways:insights from functional neuroimaging of respiratory afferents and efferents[J]. Biol Psychol, 2010, 84:13-25. [16] Lee SY, Chen MH, Chiang PL, Chen HL, Chou KH, Chen YC, Yu CC, Tsai NW, Li SH, Lu CH, Lin WC. Reduced gray matter volume and respiratory dysfunction in Parkinson's disease:a voxel-based morphometry study[J]. BMC Neurol, 2018, 18:73. [17] Oliveira LM, Tuppy M, Moreira TS, Takakura AC. Role of the locus coeruleus catecholaminergic neurons in the chemosensory control of breathing in a Parkinson's disease model[J]. Exp Neurol, 2017, 293:172-180. [18] Johnson RA, Kelm-Nelson CA, Ciucci MR. Changes to ventilation, vocalization, and thermal nociception in the Pink1-/rat model of Parkinson's disease[J]. J Parkinsons Dis, 2020, 10:489-504. [19] Batista LA, Cabral LM, Moreira TS, Takakura AC. Inhibition of anandamide hydrolysis does not rescue respiratory abnormalities observed in an animal model of Parkinson's disease[J]. Exp Physiol, 2022, 107:161-174. [20] Seccombe LM, Rogers PG, Hayes MW, Farah CS, Veitch EM, Peters MJ. Reduced hypoxic sympathetic response in mild Parkinson's disease:further evidence of early autonomic dysfunction[J]. Parkinsonism Relat Disord, 2013, 19:1066-1068. [21] Onodera H, Okabe S, Kikuchi Y, Tsuda T, Itoyama Y. Impaired chemosensitivity and perception of dyspnoea in Parkinson's disease[J]. Lancet, 2000, 356:739-740. [22] Vincken WG, Gauthier SG, Dollfuss RE, Hanson RE, Darauay CM, Cosio MG. Involvement of upper-airway muscles in extrapyramidal disorders:a cause of airflow limitation[J]. N Engl J Med, 1984, 311:438-442. [23] Docu Axelerad A, Stroe AZ, Arghir OC, Docu Axelerad D, Gogu AE. Respiratory dysfunctions in Parkinson's disease patients[J]. Brain Sci, 2021, 11:595. [24] D'Arrigo A, Floro S, Bartesaghi F, Casellato C, Sferrazza Papa GF, Centanni S, Priori A, Bocci T. Respiratory dysfunction in Parkinson's disease:a narrative review[J]. ERJ Open Res, 2020, 6:00165-02020. [25] Wang Y, Shao WB, Gao L, Lu J, Gu H, Sun LH, Tan Y, Zhang YD. Abnormal pulmonary function and respiratory muscle strength findings in Chinese patients with Parkinson's disease and multiple system atrophy:comparison with normal elderly[J]. PLoS One, 2014, 9:e116123. [26] Ma A, Lau KK, Thyagarajan D. Voice changes in Parkinson's disease:what are they telling us[J]?J Clin Neurosci, 2020, 72:1-7. [27] O Cathain E, Gaffey MM. Upper airway obstruction[M].Treasure Island:StatPearls Publishing, 2022. [28] Glass TJ, Kelm-Nelson CA, Szot JC, Lake JM, Connor NP, Ciucci MR. Functional characterization of extrinsic tongue muscles in the Pink1-/- rat model of Parkinson disease[J].PLoS One, 2020, 15:e0240366. [29] Tsai CC, Wu MN, Liou LM, Chang YP. Levodopa reverse stridor and prevent subsequent endotracheal intubation in Parkinson disease patients with bilateral vocal cord palsy:a case report[J]. Medicine (Baltimore), 2016, 95:e5559. [30] Sabaté M, González I, Ruperez F, Rodríguez M. Obstructive and restrictive pulmonary dysfunctions in Parkinson's disease[J]. J Neurol Sci, 1996, 138:114-119. [31] Sathyaprabha TN, Kapavarapu PK, Pall PK, Thennarasu K, Raju TR. Pulmonary functions in Parkinson's disease[J].Indian J Chest Dis Allied Sci, 2005, 47:251-257. [32] De Pandis MF, Starace A, Stefanelli F, Marruzzo P, Meoli I, De Simone G, Prati R, Stocchi F. Modification of respiratory function parameters in patients with severe Parkinson's disease[J]. Neurol Sci, 2002, 23 Suppl 2:69-70. [33] Florêncio RB, da Nobrega AJS, Lima íNDF, Gualdi LP, Cabral EE, Fagundes MLLC, Aliverti A, Resqueti VR, Fregonezi GAF.Chest wall volume and asynchrony in stroke and Parkinson's disease subjects:a case-control study[J]. PLoS One, 2019, 14:e0216641. [34] Kaminsky DA, Grosset DG, Kegler-Ebo DM, Cangiamilla S, Klingler M, Zhao P, Oh C. Natural history of lung function over one year in patients with Parkinson's disease[J]. Respir Med, 2021, 182:106396. [35] Santos RBD, Fraga AS, Coriolano MDGWS, Tiburtino BF, Lins OG, Esteves ACF, Asano NMJ. Respiratory muscle strength and lung function in the stages of Parkinson's disease[J]. J Bras Pneumol, 2019, 45:e20180148. [36] Martinez-Pitre PJ, Sabbula BR, Cascella M. Restrictive lung disease[M]. Treasure Island:StatPearls Publishing, 2022. [37] Parkinson's disease and Movement Disorders Group, Neurology Branch, Chinese Medical Association; Parkinson's disease and Movement Disorders Group, Neurologist Branch, Chinese Medical Doctor Association. Guidelines for the treatment of Parkinson's disease in China (4th edition)[J]. Zhonghua Shen Jing Ke Za Zhi, 2020, 53:973-986.[中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第四版)[J].中华神经科杂志, 2020, 53:973-986.] [38] Zhang W, Zhang L, Zhou N, Huang E, Li Q, Wang T, Ma C, Li B, Li C, Du Y, Zhang J, Lei X, Ross A, Sun H, Zhu X.Dysregulation of respiratory center drive (P0.1) and muscle strength in patients with early stage idiopathic Parkinson's disease[J]. Front Neurol, 2019, 10:724. [39] Baille G, Perez T, Devos D, Deken V, Defebvre L, Moreau C.Early occurrence of inspiratory muscle weakness in Parkinson's disease[J]. PLoS One, 2018, 13:e0190400. [40] de Campos PS, Hasegawa K, Kumei Y, Zeredo JL.Cineradiographic analysis of respiratory movements in a mouse model for early Parkinson's disease[J]. Respir Physiol Neurobiol, 2015, 218:40-45. [41] de Campos PS, Kawamura LRSM, Hasegawa K, Kumei Y, Zeredo JL. Analysis of respiratory movements in a mouse model of late Parkinson's disease submitted to stress[J]. Respir Physiol Neurobiol, 2018, 251:50-56. [42] Lever-van Milligen BA, Lamers F, Smit JH, Penninx BW. Six-year trajectory of objective physical function in persons with depressive and anxiety disorders[J]. Depress Anxiety, 2017, 34:188-197. [43] Lever-van Milligen BA, Lamers F, Smit JH, Penninx BWJH.Physiological stress markers, mental health and objective physical function[J]. J Psychosom Res, 2020, 133:109996. [44] Tambasco N, Murgia N, Nigro P, Paoletti FP, Romoli M, Brahimi E, Filidei M, Simoni S, Muzi G, Calabresi P. Levodoparesponsive breathing discomfort in Parkinson's disease patients[J]. J Neural Transm (Vienna), 2018, 125:1033-1036. [45] Baille G, Perez T, Devos D, Machuron F, Dujardin K, Chenivesse C, Defebvre L, Moreau C. Dyspnea is a specific symptom in Parkinson's disease[J]. J Parkinsons Dis, 2019, 9:785-791. [46] Tandon M, Ahmad FMH, Narayanan S, Mohan C, Yadav S.Impact of levodopa in lung functions in patients with Parkinson disease[J]. Ann Indian Acad Neurol, 2020, 23:338-341. [47] Monteiro L, Souza-Machado A, Valderramas S, Melo A. The effect of levodopa on pulmonary function in Parkinson's disease:a systematic review and meta-analysis[J]. Clin Ther, 2012, 34:1049-1055. [48] Weiner P, Inzelberg R, Davidovich A, Nisipeanu P, Magadle R, Berar-Yanay N, Carasso RL. Respiratory muscle performance and the perception of dyspnea in Parkinson's disease[J]. Can J Neurol Sci, 2002, 29:68-72. [49] Lim A, Leow L, Huckabee ML, Frampton C, Anderson T. A pilot study of respiration and swallowing integration in Parkinson's disease: "on" and "off" levodopa[J]. Dysphagia, 2008, 23:76-81. [50] Ko PW, Kang K, Lee HW. Levodopa-induced respiratory dysfunction confirmed by levodopa challenge test:a case report[J]. Medicine (Baltimore), 2018, 97:e12488. [51] Aubier M, Murciano D, Menu Y, Boczkowski J, Mal H, Pariente R. Dopamine effects on diaphragmatic strength during acute respiratory failure in chronic obstructive pulmonary disease[J].Ann Intern Med, 1989, 110:17-23. [52] Rice JE, Antic R, Thompson PD. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease[J]. Mov Disord, 2002, 17:524-527. [53] Hamdan AL, Khalifee E, Tabet G. Unilateral vocal fold paralysis in Parkinson disease:case report and review of the literature[J]. J Voice, 2018, 32:763-766. [54] Sun X, Dai L, Pan Y, Sha H. Upper airway obstruction during extubation after general anesthesia, in a patient with Parkinson disease:a case report[J]. Medicine (Baltimore), 2020, 99:e20363. [55] Dai LY, Pan YB, Cao XF, Ding ZN. Upper respiratory tract obstruction after general anesthesia in Parkinson's disease:a case report[J]. Lin Chuang Ma Zui Xue Za Zhi, 2019, 35:622-623.[戴乐杨,潘寅兵,曹小飞,丁正年.帕金森病全麻术后上呼吸道梗阻一例[J].临床麻醉学杂志, 2019, 35:622-623.] [56] Wang M, Saasouh W, Botsford T, Keebler A, Zura A, Benninger MS, Avitsian R. Postoperative stridor and acute respiratory failure after Parkinson disease deep brain stimulator placement:case report and review of literature[J]. World Neurosurg, 2018, 111:22-25. [57] Stocchi F, Vacca L, Grassi A, Torti M. An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson's disease[J]. Expert Opin Pharmacother, 2021, 22:965-972. [58] Shpiner DS, Bette S, Di Luca DG, Margolesky J. CVT-301 for the treatment of Parkinson's disease[J]. Expert Rev Neurother, 2019, 19:603-611. [59] Lipp MM, Hickey AJ, Langer R, LeWitt PA. A technology evaluation of CVT-301(Inbrija):an inhalable therapy for treatment of Parkinson's disease[J]. Expert Opin Drug Deliv, 2021, 18:1559-1569. [60] LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C; SPAN-PD Study Investigators. Safety and efficacy of CVT-301(levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease:a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet Neurol, 2019, 18:145-154. [61] Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson's disease patients with OFF periods:a randomized 12-month pulmonary safety study[J]. Parkinsonism Relat Disord, 2020, 71:4-10. [62] Farbman ES, Waters CH, LeWitt PA, Rudzińska M, Klingler M, Lee A, Qian J, Oh C, Hauser RA. A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease[J].Parkinsonism Relat Disord, 2020, 81:144-150. [63] Lazcano-Ocampo C, van Wamelen D, Samuel M, Silverdale M, Rizos A, Sauerbier A, Koch J, Podlewska A, Leta V, Dafsari HS, Timmermann L, Ashkan K, Ray Chaudhuri K. Evaluation of the effect of bilateral subthalamic nucleus deep brain stimulation on fatigue in Parkinson's disease as measured by the non-motor symptoms scale[J]. Br J Neurosurg, 2021, 6:1-4. [64] Dulski J, Schinwelski M, Konkel A, Grabowski K, Libionka W, W?? P, Sitek EJ, S?awek J. The impact of subthalamic deep brain stimulation on sleep and other non-motor symptoms in Parkinson's disease[J]. Parkinsonism Relat Disord, 2019, 64:138-144. [65] Bjerknes S, Toft M, Brandt R, Rygvold TW, Konglund A, Dietrichs E, Andersson S, Skogseid IM. Subthalamic nucleus stimulation in Parkinson's disease:5-year extension study of a randomized trial[J]. Mov Disord Clin Pract, 2021, 9:48-59. [66] de Noordhout AM, Mouchamps M, Remacle JM, Delstanche S, Bonhomme V, Gonce M. Subthalamic deep brain stimulation versus best medical treatment:a 12-year follow-up[J]. Acta Neurol Belg, 2022.[Epub ahead of print] [67] Sammartino F, Marsh R, Rezai A, Krishna V. Non-motor effects of subthalamic nucleus stimulation in Parkinson patients[J].Brain Imaging Behav, 2022, 16:161-168. [68] Jost ST, Sauerbier A, Visser-Vandewalle V, Ashkan K, Silverdale M, Evans J, Loehrer PA, Rizos A, Petry-Schmelzer JN, Reker P, Fink GR, Franklin J, Samuel M, Schnitzler A, Barbe MT, Antonini A, Martinez-Martin P, Timmermann L, RayChaudhuri K, Dafsari HS; EUROPAR and the International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group. A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease:results at the 36-month follow-up[J]. J Neurol Neurosurg Psychiatry, 2020, 91:687-694. [69] Diao Y, Bai Y, Hu T, Yin Z, Liu H, Meng F, Yang A, Zhang J.A meta-analysis of the effect of subthalamic nucleus-deep brain stimulation in Parkinson's disease-related pain[J]. Front Hum Neurosci, 2021, 15:688818. [70] Meoni S, Bradi AC, Wadia P, Poon YY, Moro E. Dyspnea after subthalamic deep brain stimulation in Parkinson's disease:a case-control study[J]. J Neurol, 2020, 267:3054-3060. [71] Kawaguchi M, Samura K, Miyagi Y, Okamoto T, Yamasaki R, Sakae N, Yoshida F, Iihara K. The effects of chronic subthalamic stimulation on nonmotor symptoms in advanced Parkinson's disease, revealed by an online questionnaire program[J]. Acta Neurochir (Wien), 2020, 162:247-255. [72] Yanase M, Kataoka H, Kawahara M, Hirabayashi H, Yamanaka T, Hirano M, Ueno S. Fixed epiglottis associated with subthalamic nucleus stimulation in Parkinson's disease[J]. J Neurol Neurosurg Psychiatry, 2008, 79:332-333. [73] Komiya H, Kimura K, Kishida H, Kawasaki T, Hamada K, Koizumi H, Ueda N, Tanaka F. Adjustment of subthalamic deep brain stimulation parameters improves wheeze and dyspnea in Parkinson's disease[J]. Front Neurol, 2019, 10:1317. [74] Xie T, Guan R, Staisch J, Towle VL, Warnke P. Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS[J]. Neurology, 2015, 85:479-480. [75] Oyama G, Foote KD, Iyer SS, Zeilman P, Hwynn N, Jacobson CE, Malaty IA, Fernandez HH, Rodriguez RL, Okun MS.Unilateral GPi-DBS as a treatment for levodopa-induced respiratory dyskinesia in Parkinson disease[J]. Neurologist, 2011, 17:282-285. [76] Lima JD, Sobrinho CR, Falquetto B, Santos LK, Takakura AC, Mulkey DK, Moreira TS. Cholinergic neurons in the pedunculopontine tegmental nucleus modulate breathing in rats by direct projections to the retrotrapezoid nucleus[J]. J Physiol, 2019, 597:1919-1934. [77] Lima JD, Sobrinho CR, Santos LK, Takakura AC, Moreira TS.M4-muscarinic acetylcholine receptor into the pedunculopontine tegmental nucleus mediates respiratory modulation of conscious rats[J]. Respir Physiol Neurobiol, 2019, 269:103254. [78] Fink AM, Burke LA, Sharma K. Lesioning of the pedunculopontine nucleus reduces rapid eye movement sleep, but does not alter cardiorespiratory activities during sleep, under hypoxic conditions in rats[J]. Respir Physiol Neurobiol, 2021, 288:103653. [79] Silva JN, Oliveira LM, Souza FC, Moreira TS, Takakura AC.Distinct pathways to the parafacial respiratory group to trigger active expiration in adult rats[J]. Am J Physiol Lung Cell Mol Physiol, 2019, 317:L402-413. [80] Hyam JA, Wang S, Roy H, Moosavi SH, Martin SC, Brittain JS, Coyne T, Silburn P, Aziz TZ, Green AL. The pedunculopontine region and breathing in Parkinson's disease[J]. Ann Clin Transl Neurol, 2019, 6:837-847. [81] Lenka A, Mittal SO, Lamotte G, Pagan FL. A pragmatic approach to the perioperative management of Parkinson's disease[J]. Can J Neurol Sci, 2021, 48:299-307. [82] Shen Y, Shen Y, Dong ZF, Pan PL, Shi HC, Liu CF.Obstructive sleep apnea in Parkinson's disease:a study in 239 Chinese patients[J]. Sleep Med, 2020, 67:237-243. [83] Meng L, Benedetti A, Lafontaine AL, Mery V, Robinson AR, Kimoff J, Gros P, Kaminska M. Obstructive sleep apnea, CPAP therapy and Parkinson's disease motor function:a longitudinal study[J]. Parkinsonism Relat Disord, 2020, 70:45-50. [84] Bahia CMCS, Pereira JS, Lopes AJ. Laryngopharyngeal motor dysfunction and obstructive sleep apnea in Parkinson's disease[J]. Sleep Breath, 2019, 23:543-550. [85] Sobreira-Neto MA, Pena-Pereira MA, Sobreira EST, Chagas MHN, Almeida CMO, Fernandes RMF, Tumas V, Eckeli AL.Obstructive sleep apnea and Parkinson's disease:characteristics and associated factors[J]. Arq Neuropsiquiatr, 2019, 77:609-616. [86] Sun AP, Liu N, Zhang YS, Zhao HY, Liu XL. The relationship between obstructive sleep apnea and Parkinson's disease:a systematic review and meta-analysis[J]. Neurol Sci, 2020, 41:1153-1162. [87] Sun HL, Sun BL, Chen DW, Chen Y, Li WW, Xu MY, Shen YY, Xu ZQ, Wang YJ, Bu XL. Plasma α-synuclein levels are increased in patients with obstructive sleep apnea syndrome[J].Ann Clin Transl Neurol, 2019, 6:788-794. [88] Elfil M, Bahbah EI, Attia MM, Eldokmak M, Koo BB. Impact of obstructive sleep apnea on cognitive and motor functions in Parkinson's disease[J]. Mov Disord, 2021, 36:570-580. [89] Huang JY, Zhang JR, Shen Y, Zhang HJ, Cao YL, Mao CJ, Yang YP, Chen J, Liu CF, Li J. Effect of rapid eye movement sleep behavior disorder on obstructive sleep apnea severity and cognition of Parkinson's disease patients[J]. Chin Med J (Engl), 2018, 131:899-906. [90] Kaminska M, Mery VP, Lafontaine AL, Robinson A, Benedetti A, Gros P, Kimoff RJ. Change in cognition and other non-motor symptoms with obstructive sleep apnea treatment in Parkinson disease[J]. J Clin Sleep Med, 2018, 14:819-828. [91] Harmell AL, Neikrug AB, Palmer BW, Avanzino JA, Liu L, Maglione JE, Natarajan L, Corey-Bloom J, Loredo JS, Ancoli-Israel S. Obstructive sleep apnea and cognition in Parkinson's disease[J]. Sleep Med, 2016, 21:28-34. [92] Maggi G, Trojano L, Barone P, Santangelo G. Sleep disorders and cognitive dysfunctions in Parkinson's disease:a meta-analytic study[J]. Neuropsychol Rev, 2021, 31:643-682. [93] Terzaghi M, Spelta L, Minafra B, Rustioni V, Zangaglia R, Pacchetti C, Manni R. Treating sleep apnea in Parkinson's disease with C-PAP:feasibility concerns and effects on cognition and alertness[J]. Sleep Med, 2017, 33:114-118. [94] Dunietz GL, Chervin RD, Burke JF, Braley TJ. Obstructive sleep apnea treatment disparities among older adults with neurological disorders[J]. Sleep Health, 2020, 6:534-540. [95] Castel M, Cochen De Cock V, Léon H, Dupuy-Bonafé I.Mandibular advancement device in Parkinson's disease:a pilot study on efficacy and usability[J]. Sleep Med, 2020, 66:78-81. |